233 related articles for article (PubMed ID: 12902169)
1. Will genomics revolutionise pharmaceutical R&D?
Noble D
Trends Biotechnol; 2003 Aug; 21(8):333-7. PubMed ID: 12902169
[TBL] [Abstract][Full Text] [Related]
2. Modeling the heart--from genes to cells to the whole organ.
Noble D
Science; 2002 Mar; 295(5560):1678-82. PubMed ID: 11872832
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
5. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
6. The heart is already working.
Noble D
Biochem Soc Trans; 2005 Jun; 33(Pt 3):539-42. PubMed ID: 15916559
[TBL] [Abstract][Full Text] [Related]
7. Systems biology and the heart.
Noble D
Biosystems; 2006; 83(2-3):75-80. PubMed ID: 16233947
[TBL] [Abstract][Full Text] [Related]
8. Iconix Biosciences, Inc.
Fielden MR; Halbert DN
Pharmacogenomics; 2007 Apr; 8(4):401-5. PubMed ID: 17391077
[TBL] [Abstract][Full Text] [Related]
9. Carlo Incerti.
Incerti C
Nat Rev Drug Discov; 2008 Aug; 7(8):638. PubMed ID: 18670428
[No Abstract] [Full Text] [Related]
10. Prescription for an ailing pharmaceutical industry.
Demain AL
Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
[No Abstract] [Full Text] [Related]
11. In biomarkers we trust?
Baker M
Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
[No Abstract] [Full Text] [Related]
12. From genes to whole organs: connecting biochemistry to physiology.
Noble D
Novartis Found Symp; 2001; 239():111-23; discussion 123-8, 150-9. PubMed ID: 11529307
[TBL] [Abstract][Full Text] [Related]
13. Systems biology in drug discovery.
Butcher EC; Berg EL; Kunkel EJ
Nat Biotechnol; 2004 Oct; 22(10):1253-9. PubMed ID: 15470465
[TBL] [Abstract][Full Text] [Related]
14. The end of the beginning for genomic medicine.
Bailey D; Zanders E; Dean P
Nat Biotechnol; 2001 Mar; 19(3):207-9. PubMed ID: 11231543
[No Abstract] [Full Text] [Related]
15. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical futures: a fiendish puzzle.
Abbott A
Nature; 2008 Oct; 455(7217):1164-7. PubMed ID: 18971993
[No Abstract] [Full Text] [Related]
17. Building with a scaffold: emerging strategies for high- to low-level cellular modeling.
Ideker T; Lauffenburger D
Trends Biotechnol; 2003 Jun; 21(6):255-62. PubMed ID: 12788545
[TBL] [Abstract][Full Text] [Related]
18. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
19. Discovery and development of biomarkers of neurological disease.
Dunckley T; Coon KD; Stephan DA
Drug Discov Today; 2005 Mar; 10(5):326-34. PubMed ID: 15749281
[TBL] [Abstract][Full Text] [Related]
20. The power of genomics to transform the biotechnology industry.
Haseltine WA
Nat Biotechnol; 1998 May; 16 Suppl():25-7. PubMed ID: 9591259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
